Aims To identify and synthesize evidence regarding how coronavirus disease 2019 (COVID-
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …

The COVID-19 pandemic has affected the world unprecedentedly, with both positive and
negative impacts. COVID-19 significantly impacted the immune system, and understanding …

We read with great interest the recent article in the Journal of Infection by Gentry et al., 1
which analyzed the clinical outcomes between those who received oral antivirals or not …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

We read with interest the retrospective observational study investigating the short-term effect
of oral anti-viral agents on United States Veterans aged 65 years and older who were at …

While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of
mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among …

Background Azvudine has clinical benefits and acceptable safety against COVID-19,
including in patients with comorbidities, but there is a lack of available data for its use in …

Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …

Objectives Molnupiravir and nirmatrelvir-ritonavir were the first oral antiviral agents to
demonstrate reduced hospitalization or death in patients with severe acute respiratory …

Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in
animal models of COVID-19, prompting clinical trials, in which initial results indicated a …